Tags

Type your tag names separated by a space and hit enter

Micrurus snake species: Venom immunogenicity, antiserum cross-reactivity and neutralization potential.
Toxicon. 2016 Jul; 117:59-68.T

Abstract

Micrurus snakebites can cause death by muscle paralysis and respiratory arrest a few hours after envenomation. The specific treatment for these snake envenomations is the intravenous application of heterologous antivenom. In Brazil, this antivenom is produced from horses that are immunized with a mixture of Micrurus corallinus and Micrurus frontalis venoms, which are snakes that inhabit the south and southeastern regions of the country. Previously, we demonstrated that the coral antivenom, which is used in human therapy, was not able to neutralize several of the toxic venom effects from some Micrurus species that inhabit the country, as measured by in vitro and in vivo assays. The present study aimed to investigate the immunogenic properties of Micrurus spp. venoms, as well as the cross-reactivity and neutralization potential of experimental monovalent and polyvalent sera that were produced in different animal species. The present data showed that Micrurus venoms exhibited the same immunogenicity pattern in the three utilized animal species and that the specific antisera presented a large cross-reactivity when analyzed with ELISA and Western blot assays. Nonetheless, these positive results were not well correlated with the neutralizing potential of the antisera. Thus, the establishment of a new antigenic mixture to produce novel more efficient therapeutic Micrurus antivenom is not a simple task. Further studies, particularly with the Micrurus lemniscatus, Micrurus altirostris and Micrurus surinamensis venoms, are necessary to establish new strategies for the production of antivenoms with broad neutralizing activity for the treatment of accidents involving coral snakes throughout the country.

Authors+Show Affiliations

Laboratório de Imunoquímica, Butantan Institute, São Paulo, SP, Brazil.Laboratório de Imunoquímica, Butantan Institute, São Paulo, SP, Brazil.Seção de Plasmas Hiperimunes, Butantan Institute, São Paulo, SP, Brazil.Seção de Plasmas Hiperimunes, Butantan Institute, São Paulo, SP, Brazil.Laboratório de Herpetologia, Butantan Institute, São Paulo, SP, Brazil.Laboratório de Imunoquímica, Butantan Institute, São Paulo, SP, Brazil. Electronic address: denise.tambourgi@butantan.gov.br.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27045363

Citation

Tanaka, Gabriela D., et al. "Micrurus Snake Species: Venom Immunogenicity, Antiserum Cross-reactivity and Neutralization Potential." Toxicon : Official Journal of the International Society On Toxinology, vol. 117, 2016, pp. 59-68.
Tanaka GD, Sant'Anna OA, Marcelino JR, et al. Micrurus snake species: Venom immunogenicity, antiserum cross-reactivity and neutralization potential. Toxicon. 2016;117:59-68.
Tanaka, G. D., Sant'Anna, O. A., Marcelino, J. R., Lustoza da Luz, A. C., Teixeira da Rocha, M. M., & Tambourgi, D. V. (2016). Micrurus snake species: Venom immunogenicity, antiserum cross-reactivity and neutralization potential. Toxicon : Official Journal of the International Society On Toxinology, 117, 59-68. https://doi.org/10.1016/j.toxicon.2016.03.020
Tanaka GD, et al. Micrurus Snake Species: Venom Immunogenicity, Antiserum Cross-reactivity and Neutralization Potential. Toxicon. 2016;117:59-68. PubMed PMID: 27045363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Micrurus snake species: Venom immunogenicity, antiserum cross-reactivity and neutralization potential. AU - Tanaka,Gabriela D, AU - Sant'Anna,Osvaldo Augusto, AU - Marcelino,José Roberto, AU - Lustoza da Luz,Ana Cristina, AU - Teixeira da Rocha,Marisa Maria, AU - Tambourgi,Denise V, Y1 - 2016/04/01/ PY - 2016/02/26/received PY - 2016/03/24/revised PY - 2016/03/31/accepted PY - 2016/4/6/entrez PY - 2016/4/6/pubmed PY - 2017/5/19/medline KW - Antivenom KW - Cross-reactivity KW - Immunogenecity KW - Micrurus spp. KW - Neutralization potential KW - Snake venoms SP - 59 EP - 68 JF - Toxicon : official journal of the International Society on Toxinology JO - Toxicon VL - 117 N2 - Micrurus snakebites can cause death by muscle paralysis and respiratory arrest a few hours after envenomation. The specific treatment for these snake envenomations is the intravenous application of heterologous antivenom. In Brazil, this antivenom is produced from horses that are immunized with a mixture of Micrurus corallinus and Micrurus frontalis venoms, which are snakes that inhabit the south and southeastern regions of the country. Previously, we demonstrated that the coral antivenom, which is used in human therapy, was not able to neutralize several of the toxic venom effects from some Micrurus species that inhabit the country, as measured by in vitro and in vivo assays. The present study aimed to investigate the immunogenic properties of Micrurus spp. venoms, as well as the cross-reactivity and neutralization potential of experimental monovalent and polyvalent sera that were produced in different animal species. The present data showed that Micrurus venoms exhibited the same immunogenicity pattern in the three utilized animal species and that the specific antisera presented a large cross-reactivity when analyzed with ELISA and Western blot assays. Nonetheless, these positive results were not well correlated with the neutralizing potential of the antisera. Thus, the establishment of a new antigenic mixture to produce novel more efficient therapeutic Micrurus antivenom is not a simple task. Further studies, particularly with the Micrurus lemniscatus, Micrurus altirostris and Micrurus surinamensis venoms, are necessary to establish new strategies for the production of antivenoms with broad neutralizing activity for the treatment of accidents involving coral snakes throughout the country. SN - 1879-3150 UR - https://www.unboundmedicine.com/medline/citation/27045363/Micrurus_snake_species:_Venom_immunogenicity_antiserum_cross_reactivity_and_neutralization_potential_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-0101(16)30059-9 DB - PRIME DP - Unbound Medicine ER -